August 16th 2025
Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.
Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.
Proteasome Inhibitors Show Promise as Treatment for Multiple Myeloma
CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapy
Dr C. Ola Landgren Discusses Identification of Smoldering Myeloma